Publications by authors named "Judit Pich"

Claim this Profile
S
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.
Elisa Pose, César Jiménez, Giacomo Zaccherini, Daniela Campion, Salvatore Piano, Judit Pich

JAMA· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
Lorna Leal, Judit Pich, Laura Ferrer, Jocelyn Nava, Ruth Martí-Lluch

NPJ Vaccines· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries.
Isabel Graupera, Maja Thiele, Ann T Ma, Miquel Serra-Burriel, Judit Pich

BMC Public Health· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries.
Isabel Graupera, Maja Thiele, Ann T Ma, Miquel Serra-Burriel, Judit Pich

BMC Public Health· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
Lorna Leal, Elvira Couto, Sonsoles Sánchez-Palomino, Núria Climent, Irene Fernández, Judit Pich

Front Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
Pere Ginès, Laurent Castera, Frank Lammert, Isabel Graupera, Miquel Serra-Burriel, Judit Pich

Hepatology· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
Elisa Pose, Laura Napoleone, Ahmed Amin, Daniela Campion, César Jimenez, Judit Pich

Lancet Gastroenterol Hepatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B.
Elvira Couto, Vicenç Diaz-Brito, Beatriz Mothe, Alberto C Guardo, Irene Fernandez, Judit Pich

Vaccines (Basel)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection.
Lorna Leal, Alberto C Guardo, Sara Morón-López, Maria Salgado, Beatriz Mothe, Judit Pich

AIDS· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
Alberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, Judit Pich, Joan Albert Arnaiz

PLoS One· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
Alberto C Guardo, Carmen Elena Gómez, Vicens Díaz-Brito, Judit Pich, Joan Albert Arnaiz

PLoS One· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Lorna Leal, Agathe León, Berta Torres, Alexy Inciarte, Constanza Lucero, Judit Pich

J Antimicrob Chemother· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Lorna Leal, Agathe León, Berta Torres, Alexy Inciarte, Constanza Lucero, Judit Pich

J Antimicrob Chemother· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
Beatriz Mothe, Nuria Climent, Montserrat Plana, Miriam Rosàs, José Luis Jiménez, Judit Pich

J Antimicrob Chemother· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
José R Arribas, Pierre-Marie Girard, Roland Landman, Judit Pich, Josep Mallolas

Lancet Infect Dis· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
Esteban Martinez, Ana Gonzalez-Cordon, Elena Ferrer, Pere Domingo, Eugenia Negredo, Judit Pich

Clin Infect Dis· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.
Esteban Martínez, Polyana M d'Albuquerque, Ignacio Pérez, Judit Pich, José M Gatell

AIDS Res Hum Retroviruses· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
Polyana Monteiro, Iñaki Perez, Judit Pich, Jose Maria Gatell, Esteban Martínez

J Antimicrob Chemother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.
Esteban Martínez, Polyana M D'Albuquerque, Josep M Llibre, Felix Gutierrez, Daniel Podzamczer, Judit Pich

AIDS· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country.
Maria Constanza Lucero, Vicens Diaz-Brito, Berta Torres Murillo, Saray Corral Carretero, Marta Sala, Judit Pich

AIDS Patient Care STDS· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
Felipe García, Juan Carlos López Bernaldo de Quirós, Carmen E Gómez, Beatriz Perdiguero, Jose L Nájera, Judit Pich

Vaccine· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Esteban Martínez, María Larrousse, Josep M Llibre, Felix Gutiérrez, Maria Saumoy, Judit Pich

AIDS· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Esteban Martínez, María Larrousse, Daniel Podzamczer, Ignacio Pérez, Félix Gutiérrez, Judit Pich

AIDS· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Esteban Martínez, José A Arranz, Daniel Podzamczer, Montserrat Loncá, José Sanz, Judit Pich

J Acquir Immune Defic Syndr· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Josep Mallolas, Daniel Podzamczer, Ana Milinkovic, Pere Domingo, Bonaventura Clotet, Judit Pich

J Acquir Immune Defic Syndr· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis